BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
April 18 2016 - 10:21AM
What:
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global
biotechnology company that develops and commercializes innovative
therapies for patients with serious and life-threatening rare and
ultra-rare genetic diseases, will visit the Nasdaq MarketSite in
Times Square for a Research & Development Event on April
20.
In honor of the occasion, Jean-Jacques Bienaime,
Chairman and CEO, will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Tuesday, April 19, 2016 – 3:45 p.m. to 4:00 p.m.
ET
BioMarin Media Contact:Debra Charlesworth(415)
455-7451DCharlesworth@bmrn.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:http://instagram.com/nasdaq
For livestream of ceremonies and events visit our YouTube
Page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page
at:http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit our Tumblr
Page:http://nasdaq.tumblr.com/
Webcast: A LiveStream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare and ultra-rare genetic diseases. The
company's portfolio consists of five commercialized products and
multiple clinical and pre-clinical product candidates. For
additional information, please visit www.BMRN.com. Information on
BioMarin's website is not incorporated by reference into this press
release.
About NASDAQ-100 Index®
The NASDAQ-100 Index, launched in January 1985, is one of the
most widely followed benchmarks in the world. The NASDAQ-100 Index
is the basis of the PowerShares QQQ Trust (Nasdaq:QQQ) which aims
to provide investment results that, before expenses, correspond
with the NASDAQ-100 Index's performance. In addition, options,
futures and structured products based on the NASDAQ-100 Index and
the PowerShares QQQ Trust trade on various exchanges.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic
stock market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.6 trillion and nearly 10,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024